BIVI Latest Press Releases

-- September 15, 2026 --

BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID Globe Newswire 7:30 AM

-- September 14, 2026 --

BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid Globe Newswire 4:01 PM

-- September 8, 2026 --

BioVie Announces Update to Parkinson's Phase 3 Development Program Globe Newswire 7:30 AM

-- August 31, 2026 --

BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID Globe Newswire 8:00 AM

-- August 6, 2026 --

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease Globe Newswire 7:30 AM

-- June 5, 2026 --

Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? PRNewswire 3:31 PM

-- May 27, 2026 --

Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2 Globe Newswire 8:00 AM

-- May 26, 2026 --

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID Globe Newswire 8:00 AM

-- May 18, 2026 --

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software